Patent: 9,700,486

Summary for Patent: 9,700,486

Title:	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Abstract:	The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, GAMMAGARD LIQUID (an immune globulin infusion (human)); ADVATE (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, (rAHF)); BAX 111 (vonicog alfa, or [618-threonine,709-aspartic acid] von Willebrand factor Homo sapiens (1381A>T,1472H>D variant)); or an adeno-associated viral vector containing a liver-specific human factor IX expression cassette, e.g., sscAAV2/8-LP1-hFIXco.
Inventor(s):	Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY)
Assignee:	Corning Incorporated (Corning, NY)
Application Number:	14/259,273
Patent Claims:	see list of patent claims

United States Patent 9,700,486 claims and patent landscape analysis

US 9,700,486 is a container-centric pharmaceutical product claim set. It covers a pharmaceutical composition for biologics (including recombinant antihemophilic factor, recombinant von Willebrand factor, and an sscAAV2/8-LP1-hFIXco gene therapy) when packaged in a high-stiffness, specifically-composed glass container defined by tight glass chemistry constraints (SiO2, MgO/CaO balance, Al2O3 window, Na2O threshold, and a B2O3 ratio rule) plus optional performance requirements (compressive stress, depth of layer, substantially boron-free, and inner-layer structure). The legal and commercial risk is driven more by glass/container design choices and fill-finish validation than by the active substances named in the claim.

---

What does US 9,700,486 claim, and what parts are actually limiting?

Core claim 1 limitation is a conjunctive combination of:

1. Product/biologic identity (pharmaceutical composition comprising immune globulin infusion; or antihemophilic factor recombinant; or recombinant von Willebrand factor rVWF; or sscAAV2/8-LP1-hFIXco self-complementary AAV vector with liver-specific human Factor IX expression cassette) and
2. A pharmaceutically acceptable excipient and
3. A glass pharmaceutical container that satisfies a specific glass composition (chemistry ranges + ratio test) and is the container “comprising” those components, and
4. The composition is “contained within” the glass container.

Why this matters for claim construction

• Claim 1 is not “a product containing biologics in any glass.” It is “a product containing biologics in a glass container with defined chemistry.”
• The biologics list functions like a permitted payload. The glass definitions are the likely bottleneck for non-infringement.
• Dependent claims 2–4 and 6–12 add performance/structural constraints (compressive stress, depth, boron absence, layered homogeneity), giving multiple fall-back narrowing points for validity defense and multiple design-around opportunities.

---

What glass-chemistry limitations define infringement risk under claim 1?

Glass composition constraints in claim 1 (as stated):

• SiO2: ≥ about 72 mol % and ≤ about 78 mol %
• Alkaline earth oxide includes MgO and CaO
  • CaO: up to about 1.0 mol %
  • ratio rule: CaO(mol%)/(CaO+MgO)(mol%) ≤ 0.5
• Al2O3: X mol % where X is about 5 to 7 mol %
• Alkali oxide comprises Na2O:
  • Na2O: > about 8 mol %
  • Y mol % alkali oxide with Na2O in that amount (claim wording ties Na2O to alkali oxide)
• B2O3 ratio rule:
  • (B2O3 mol %)/( (Y mol %) − (X mol %) ) ≤ 0.3

Practical effect: infringement hinges on meeting all ratio/threshold tests

A design-around strategy that avoids infringement can focus on any single material limit in the glass formula, because claim 1 requires the glass container to have the claimed chemistry “comprising” those ranges/ratios. The most actionable levers are:

• Al2O3: outside 5–7 mol % breaks claim 1.
• Na2O: keep Na2O at or below 8 mol % or adjust alkali oxide definition.
• B2O3 ratio: adjust B2O3 relative to (Y − X).
• CaO/MgO balance: CaO up to 1.0 mol % is already tight, and the ratio ≤0.5 further restricts CaO relative to MgO.

---

How do claims 2–4 change the infringement map (compressive stress and layer depth)?

Claim 2: compressive stress ≥ 150 MPa
Claim 3: compressive stress ≥ 250 MPa
Claim 4: depth of layer > 30 μm

These add process/performance characteristics of the container surface and strengthens enforceability by moving from chemistry-only to chemistry + mechanical surface treatment. For container manufacturers, compressive stress and layer depth are usually tied to:

• ion exchange protocols (often Na+ for other ions),
• heat-treatment schedules,
• and whether the article is fully tempered vs. chemically strengthened.

From a legal standpoint:

• If a competitor’s glass chemistry falls within claim 1 but its compressive stress or surface depth is lower, it may avoid dependent claims even if claim 1 remains at issue.
• If the chemistry does not meet claim 1, then dependent claims become irrelevant for infringement.

---

What do claims 5–12 add about stability and container structure?

“Increased stability/integrity/efficacy” (claim 5) as a comparative functional limitation

Claim 5: increased stability, product integrity, or efficacy compared to the same composition not contained within the glass container.

This can create evidentiary burden and a validity argument depending on how “increased” is measured and whether the effect is attributable to the container versus formulation. In claim litigation, it can also complicate claim construction: it can invite disputes about comparators and test conditions.

“Substantially free of boron” (claims 7 and 8–9)

Claim 7: substantially free of boron
Claim 8: compressive stress ≥150 MPa and depth >25 μm
Claim 9: compressive stress ≥300 MPa and depth >35 μm

These claims narrow to very specific container variants, and they can also create a paradox for claim 1 because claim 1 already has a B2O3 ratio test. A “substantially boron-free” container can still satisfy claim 1 if the B2O3 ratio remains ≤0.3, but it reduces the risk that a competitor will accidentally fall into the boron-controlled region.

Layer architecture (claims 10–12)

• Claim 10: substantially homogeneous inner layer
• Claim 11: (depends on claim 10) compressive stress ≥150 MPa and depth >25 μm
• Claim 12: internal homogeneous layer

These are structural design constraints that can be tested by microscopy and surface profiling. They are also strongly tied to container manufacturing steps and can be used as design-around points through:

• altered ion exchange penetration profiles,
• or layered heterogeneity.

---

Is US 9,700,486 directed to biologics, or to drug-device/container IP?

The claims are structurally device/container-centric. The biologic payload is a list of possible active substances, but the limiting elements are:

• the glass composition ranges and ratios, and
• mechanical/structural properties of the glass container.

This matters in the patent landscape: many competing gene therapy and biologic products can share payload classes, but container glass formulations can vary meaningfully by manufacturer and drug product technical package. As a result, enforcement and freedom-to-operate (FTO) analysis should be treated as a packaging IP exercise, not as a biologic composition IP exercise.

---

What products could fall within the payload list (and why that list is broad)?

Claim 1 permits these “immune globulin infusion” / biologic candidates:

• immune globulin infusion
• antihemophilic factor (recombinant)
• recombinant von Willebrand factor (rVWF)
• sscAAV2/8-LP1-hFIXco gene therapy (self-complementary AAV2/8 with LP1 liver-specific hFIX expression cassette)
• plus excipient and container.

The inclusion of sscAAV2/8-LP1-hFIXco is the most specific payload. But the claim is not limited to Factor IX alone. If competitors package other biologics in qualifying glass, they can still face exposure, provided the entire claim 1 container composition and optional dependent features are met.

---

How many patent “attack angles” exist for US 9,700,486: chemistry, strengthening, structure, and evidence

Even without other listed claims, the structure implies multiple infringement/validity angles:

Infringement angles

• Chemistry meet-or-does-not meet: SiO2, Al2O3, Na2O threshold, CaO cap and CaO/(CaO+MgO) ratio, B2O3 ratio test
• Surface/mechanical properties: compressive stress thresholds and layer depth
• Structural homogeneity: homogeneous inner layer / internal homogeneous layer
• “Substantially boron-free” status
• Comparative evidence: stability/integrity/efficacy increase tied to comparator

Validity angles

• If the glass chemistry ranges and strengthening methods are already disclosed for pharmaceutical containers, novelty/inventive step may be attacked as obvious combination or lack of inventive contribution.
• If “substantially free of boron” lacks a clear definition, enablement/indefiniteness arguments may be available depending on prosecution history and specification support.
• If the stability/efficacy advantage is not robustly supported across all payloads, validity defenses may be strengthened.

---

What does a “design-around” strategy look like for competitors?

Because claim 1 is conjunctive, there are several straightforward design paths:

1. Change glass chemistry outside any single constrained window

   • Al2O3 outside 5–7 mol %
   • Na2O at or below 8 mol % (if “greater than about 8” is interpreted as >8)
   • Adjust CaO/MgO ratio to exceed the ≤0.5 constraint
   • Adjust B2O3 relative to (Y − X) to exceed the ≤0.3 ratio

2. Avoid dependent mechanical performance targets

   • Keep compressive stress below 150 MPa or 250 MPa, depending on target risk
   • Keep layer depth at or below 30 μm (or the higher thresholds tied to boron-free claims)

3. Avoid structural homogeneity

   • Use a container process that does not produce a “substantially homogeneous inner layer”
   • Use controlled heterogeneity or different exchange depth profiles

4. Avoid boron-free classification

   • Use boron-containing glass variants that are not “substantially free of boron,” while still staying within safe product stability requirements

In litigation posture, competitors typically prefer a chemistry-based or structural-based non-infringement position because it avoids contested comparative stability tests.

---

What is the likely litigation and regulatory relevance?

Regulatory link is indirect but powerful:

• If the drug product sponsor submitted container/closure system details and stability data to FDA, the container “as manufactured” becomes central to both regulatory comparability and litigation discovery.
• For gene therapies (including AAV vectors), stability and delivery device interactions matter, so the container IP can become part of the CMC record, increasing discoverability of:
  • glass formulation,
  • strengthening parameters,
  • layer depth,
  • and boron content characterization.

Litigation relevance depends on whether the enforcement target is:

• the sponsor marketing the payload product,
• the contract fill-finish or container supplier,
• or both.

Because the claim is product “comprising” a glass container, the sponsor’s supply chain is an enforcement target.

---

Where does US 9,700,486 sit among typical US patent estate layers?

For a packaging-centric claim like this, the likely adjacent patent estate elements (in practice) include:

• separate patents on pharmaceutical glass chemistry suitable for parenterals,
• patents on chemical strengthening and ion exchange methods achieving specified compressive stress and layer depth,
• and patents on layered or boron-free glass compositions.

US 9,700,486 appears to combine:

• a narrowly defined glass chemistry recipe
• with performance metrics (compressive stress, depth) and optional structural descriptors (homogeneous inner layer) plus a stability advantage.

That combination can be harder to invalidate than a single generic glass-chemistry disclosure but also hard to prove if the evidentiary record does not show the claimed advantage.

---

How does this affect biosimilar or generic entry risk?

Generics

A small molecule generic in itself is not the driver; the claim is triggered by the biologic payload list and the container. Still, if a generic biologic-like product is not in the payload list, it can fall outside claim 1 even if it uses the same container.

Biosimilars

Biosimilars and replacement biologics face container IP risk if they:

• are within the listed payload types (eg, recombinant antihemophilic factor or rVWF) and
• use a glass container matching the claim chemistry and optional mechanical/structural features.

Gene therapy

Gene therapy is the most sensitive segment. If a competitor develops an AAV gene therapy whose sponsor selects a qualifying glass container, US 9,700,486 becomes a direct packaging/IP barrier.

---

How strong is the patent estate for US 9,700,486 based on claim structure?

Strength indicators:

• Tight glass chemistry and ratio constraints can reduce the “known glass world” coverage and make it harder for competitors to argue they are covered only in theory.
• Dependent claims create layered narrow fallback positions on measurable mechanical properties and structural characteristics.

Potential weaknesses baked into the claims:

• “Increased stability/integrity/efficacy” is a functional comparative limitation that can be attacked as not necessarily tied to the claimed glass parameters.
• Broad payload list plus single container-focused limitation can create scope challenges if prior art is broad on container glass and strengthening while the stability advantage is weakly supported.

---

Claim-by-claim infringement checklist for US 9,700,486 (actionable FTO framing)

Claim 1 (base exposure)

A product would infringe only if all are true:

• payload is within claim 1 list
• glass container meets:
  • SiO2 72–78 mol %
  • Al2O3 5–7 mol %
  • MgO/CaO with CaO ≤1.0 mol % and CaO/(CaO+MgO) ≤0.5
  • Na2O >8 mol %
  • B2O3 ratio ≤0.3 where denominator is (Y − X)

Claim 2 and Claim 3 (higher mechanical stress)

• claim 1 satisfied
• compressive stress ≥150 MPa (claim 2) and/or ≥250 MPa (claim 3)

Claim 4 and Claim 6 (depth rules)

• claim 1 satisfied
• depth >30 μm (claim 4)
• claim 6 adds compressive stress ≥150 MPa with depth >10 μm

Claims 7–9 (boron-free plus higher stress/depth)

• claim 1 satisfied
• “substantially free of boron” (claim 7)
• claim 8: ≥150 MPa and depth >25 μm
• claim 9: ≥300 MPa and depth >35 μm

Claims 10–12 (layer homogeneity)

• claim 1 satisfied
• substantially homogeneous inner layer (claim 10) or internal homogeneous layer (claim 12)
• plus claim 11: ≥150 MPa and depth >25 μm

---

Key Takeaways

• US 9,700,486 is primarily an IP claim on pharmaceutical glass container chemistry plus strengthening/structure, not on the biologic itself.
• Claim 1 is governed by tight glass composition windows and ratio constraints (SiO2, Al2O3, Na2O, MgO/CaO balance, and B2O3 ratio).
• Dependent claims add measurable mechanical and structural features (compressive stress thresholds, layer depth, substantially boron-free, homogeneous inner layer).
• Design-around is achievable by adjusting any single constrained glass parameter or by selecting strengthening processes that miss compressive stress/layer depth or layer homogeneity descriptors.
• Commercial and litigation risk is highest where sponsors and fill-finish/container suppliers use the exact qualifying glass recipe and surface properties for AAV and other listed recombinant biologics.

---

FAQs

1. What evidence is most likely required to prove infringement for US 9,700,486?
   Glass chemistry characterization (molar percent for SiO2, Al2O3, MgO, CaO, Na2O, B2O3), compressive stress measurement, surface layer depth profiling, and layer homogeneity testing, tied to the specific container supplied for the accused product.

2. Can a competitor avoid claim 1 by altering only boron levels?
   Yes, if the altered glass does not satisfy the B2O3 ratio rule in claim 1 or fails the “substantially free of boron” limitations in claims 7–9.

3. Do compressive stress and depth requirements matter if glass chemistry is non-matching?
   No. If claim 1 glass composition is not met, dependent claims are not reached.

4. How does the stability/effectiveness comparative language affect litigation posture?
   It can become a contested evidentiary issue, since infringement arguments may rely on the presence of “increased stability, product integrity, or efficacy” compared with the same composition not in the claimed glass.

5. Is the patent relevant to any recombinant antihemophilic factor or rVWF product?
   Potentially, but only when the product uses the claimed glass container chemistry and (for dependent claims) meets the additional stress/depth/structure/borderline boron constraints.

---

References

1. United States Patent 9,700,486, “pharmaceutical product comprising immune globulin infusion; antihemophilic factor (recombinant); recombinant von Willebrand factor (rVWF); or sscAAV2/8-LP1-hFIXco…” (claims as provided).

Details for Patent 9,700,486

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332	August 20, 2002	9,700,486	2034-04-23
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332	June 07, 2007	9,700,486	2034-04-23
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332	July 31, 2009	9,700,486	2034-04-23